AUTL01

AUTL01 is a preclinical **CAR-T cell therapy** being developed by **Autolus** in collaboration with **Noile-Immune**. The program is listed as a co-pipeline asset on Noile-Immune's pipeline and is directed against an **undisclosed tumor antigen**. Based on the disclosed collaboration context, the product is intended to mediate **T cell-driven tumor cell killing** and is likely designed using Noile-Immune's **PRIME CAR-T** platform features, which are intended to enhance CAR-T cell proliferation and trafficking, particularly for solid tumors, through secretion of IL-7 and CCL19. No disease indication, brand name, or precise molecular target has been publicly disclosed, and the program remains in **preclinical development**.

Other names

AUTL01-Autolus-undisclosed-CAR-T cell therapyAUTL-01-Autolus-undisclosed-CAR-T cell therapyAUTL 01-Autolus-undisclosed-CAR-T cell therapy